L. Kerr

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

L. Coates, A. Orbai, D. Adams, 2018, BMC Rheumatology.

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.

S. Ball, K. Reich, A. Blauvelt, 2018, The Journal of investigative dermatology.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

U. Wagner, A. Gottlieb, A. Orbai, 2017, The Lancet.

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

J. Kremer, M. Genovese, T. Tsai, 2018, Rheumatology.

Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)

M. Lebwohl, F. Kerdel, K. Reich, 2017, The Journal of dermatological treatment.

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study

L. Coates, S. Pillai, P. Mease, 2021, Arthritis & rheumatology.

056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2

D. Shrom, A. Menter, K. Reich, 2016 .

ixekizumab, a novel anti–il-17a antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis : 3232

T. Luger, K. Reich, K. Gordon, 2016 .